FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005267039> ?p ?o ?g. }

• W2005267039 abstract "In the present study, we prepared a novel delivery system of iRGD (CRGDK/RGPD/EC)-modified sterically stabilized liposomes (SSLs) containing conjugated linoleic acid-paclitaxel (CLA-PTX). The anti-tumor effect of iRGD-SSL-CLA-PTX was investigated on B16-F10 melanoma in vitro and in vivo. The in vitro targeting effect of iRGD-modified SSLs was investigated in a real-time confocal microscopic analysis experiment. An endocytosis-inhibition assay was used to evaluate the endocytosis pathways of the iRGD-modified SSLs. In addition, the in vitro cellular uptake and in vitro cytotoxicity of iRGD-SSL-CLA-PTX were evaluated in B16-F10 melanoma cells. In vivo biodistribution and in vivo antitumor effects of iRGD-SSL-CLA-PTX were investigated in B16-F10 tumor-bearing mice. The induction of apoptosis by iRGD-SSL-CLA-PTX was evaluated in tumor-tissue sections. Real-time confocal microscopic analysis results indicated that the iRGD-modified SSLs internalized into B16-F10 cells faster than SSLs. The identified endocytosis pathway of iRGD-modified SSLs indicated that energy- and lipid raft-mediated endocytosis played a key role in the liposomes' cellular uptake. The results of the cellular uptake experiment indicated that the increased cellular uptake of CLA-PTX in the iRGD-SSL-CLA-PTX-treated group was 1.9-, 2.4-, or 2.1-fold compared with that in the CLA-PTX group after a 2-, 4-, or 6-hour incubation, respectively. In the biodistribution test, the CLA-PTX level in tumor tissues from iRGD-SSL-CLA-PTX-treated mice at 1 hour (1.84±0.17 μg/g) and 4 hours (1.17±0.28 μg/g) was 2.3- and 2.0-fold higher than that of CLA-PTX solution at 1 hour (0.79±0.06 μg/g) and 4 hours (0.58±0.04 μg/g). The value of the area under the curve for the first 24 hours in the tumors of iRGD-SSL-CLA-PTX-treated mice was significantly higher than that in the SSL-CLA-PTX and CLA-PTX solution-treated groups (P<0.01). The in vivo antitumor results indicated that iRGD-SSL-CLA-PTX significantly inhibited the growth of B16-F10 tumors compared with the SSL-CLA-PTX or CLA-PTX solution-treatment groups (P<0.01). The results of tumor-cell apoptosis showed that tumors from the iRGD-SSL-CLA-PTX-treated group exhibited more advanced cell apoptosis compared with the control, CLA-PTX solution-, and SSL-CLA-PTX-treated groups. In conclusion, the antitumor effect of iRGD-SSL-CLA-PTX was confirmed on B16-F10 melanoma in vitro and in vivo." @default.
• W2005267039 created "2016-06-24" @default.
• W2005267039 creator A5016622484 @default.
• W2005267039 creator A5026082800 @default.
• W2005267039 creator A5038994209 @default.
• W2005267039 creator A5039837606 @default.
• W2005267039 creator A5045543880 @default.
• W2005267039 creator A5049575988 @default.
• W2005267039 creator A5055838753 @default.
• W2005267039 creator A5062774362 @default.
• W2005267039 creator A5067534896 @default.
• W2005267039 creator A5090070709 @default.
• W2005267039 date "2014-06-01" @default.
• W2005267039 modified "2023-09-26" @default.
• W2005267039 title "Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma" @default.
• W2005267039 cites W1575138345 @default.
• W2005267039 cites W1633153155 @default.
• W2005267039 cites W1963618034 @default.
• W2005267039 cites W1964323929 @default.
• W2005267039 cites W1967637067 @default.
• W2005267039 cites W1968754817 @default.
• W2005267039 cites W1978880171 @default.
• W2005267039 cites W1981057288 @default.
• W2005267039 cites W1984466684 @default.
• W2005267039 cites W1985215977 @default.
• W2005267039 cites W1997485317 @default.
• W2005267039 cites W1999491660 @default.
• W2005267039 cites W1999813833 @default.
• W2005267039 cites W2003212059 @default.
• W2005267039 cites W2011350835 @default.
• W2005267039 cites W2011370547 @default.
• W2005267039 cites W2013662870 @default.
• W2005267039 cites W2021162665 @default.
• W2005267039 cites W2025344276 @default.
• W2005267039 cites W2026095095 @default.
• W2005267039 cites W2026855866 @default.
• W2005267039 cites W2033612573 @default.
• W2005267039 cites W2038626534 @default.
• W2005267039 cites W2039508369 @default.
• W2005267039 cites W2047311244 @default.
• W2005267039 cites W2047925052 @default.
• W2005267039 cites W2053649039 @default.
• W2005267039 cites W2053781426 @default.
• W2005267039 cites W2054361195 @default.
• W2005267039 cites W2057932988 @default.
• W2005267039 cites W2063335180 @default.
• W2005267039 cites W2070994004 @default.
• W2005267039 cites W2092147170 @default.
• W2005267039 cites W2095142763 @default.
• W2005267039 cites W2104808978 @default.
• W2005267039 cites W2113972541 @default.
• W2005267039 cites W2116075431 @default.
• W2005267039 cites W2123647020 @default.
• W2005267039 cites W2129144690 @default.
• W2005267039 cites W2158794014 @default.
• W2005267039 cites W2163326536 @default.
• W2005267039 cites W2207270974 @default.
• W2005267039 cites W2210985609 @default.
• W2005267039 cites W2322622621 @default.
• W2005267039 doi "https://doi.org/10.2147/ijn.s65664" @default.
• W2005267039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4077607" @default.
• W2005267039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25028548" @default.
• W2005267039 hasPublicationYear "2014" @default.
• W2005267039 type Work @default.
• W2005267039 sameAs 2005267039 @default.
• W2005267039 citedByCount "16" @default.
• W2005267039 countsByYear W20052670392015 @default.
• W2005267039 countsByYear W20052670392016 @default.
• W2005267039 countsByYear W20052670392017 @default.
• W2005267039 countsByYear W20052670392018 @default.
• W2005267039 countsByYear W20052670392019 @default.
• W2005267039 countsByYear W20052670392020 @default.
• W2005267039 countsByYear W20052670392021 @default.
• W2005267039 countsByYear W20052670392023 @default.
• W2005267039 crossrefType "journal-article" @default.
• W2005267039 hasAuthorship W2005267039A5016622484 @default.
• W2005267039 hasAuthorship W2005267039A5026082800 @default.
• W2005267039 hasAuthorship W2005267039A5038994209 @default.
• W2005267039 hasAuthorship W2005267039A5039837606 @default.
• W2005267039 hasAuthorship W2005267039A5045543880 @default.
• W2005267039 hasAuthorship W2005267039A5049575988 @default.
• W2005267039 hasAuthorship W2005267039A5055838753 @default.
• W2005267039 hasAuthorship W2005267039A5062774362 @default.
• W2005267039 hasAuthorship W2005267039A5067534896 @default.
• W2005267039 hasAuthorship W2005267039A5090070709 @default.
• W2005267039 hasBestOaLocation W20052670391 @default.
• W2005267039 hasConcept C109316439 @default.
• W2005267039 hasConcept C121608353 @default.
• W2005267039 hasConcept C126322002 @default.
• W2005267039 hasConcept C1491633281 @default.
• W2005267039 hasConcept C150903083 @default.
• W2005267039 hasConcept C185154212 @default.
• W2005267039 hasConcept C185592680 @default.
• W2005267039 hasConcept C190283241 @default.
• W2005267039 hasConcept C202751555 @default.
• W2005267039 hasConcept C207001950 @default.
• W2005267039 hasConcept C2777292972 @default.
• W2005267039 hasConcept C2777807558 @default.
• W2005267039 hasConcept C2779780233 @default.
• W2005267039 hasConcept C2780809830 @default.

• next